BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38823390)

  • 1. Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface.
    Wolters RM; Ferguson JA; Nuñez IA; Chen EE; Sornberger T; Myers L; Oeverdieck S; Raghavan SSR; Kona C; Handal LS; Esilu TE; Davidson E; Doranz BJ; Engdahl TB; Kose N; Williamson LE; Creech CB; Gibson-Corley KN; Ward AB; Crowe JE
    Immunity; 2024 Jun; 57(6):1413-1427.e9. PubMed ID: 38823390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
    Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
    Madsen A; Dai YN; McMahon M; Schmitz AJ; Turner JS; Tan J; Lei T; Alsoussi WB; Strohmeier S; Amor M; Mohammed BM; Mudd PA; Simon V; Cox RJ; Fremont DH; Krammer F; Ellebedy AH
    Immunity; 2020 Oct; 53(4):852-863.e7. PubMed ID: 32976769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model.
    Tan J; O'Dell G; Hernandez MM; Sordillo EM; Kahn Z; Kriti D; van Bakel H; Ellebedy AH; Wilson PC; Simon V; Krammer F; McMahon M
    J Virol; 2022 Jan; 96(2):e0142121. PubMed ID: 34669506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
    Jiang L; Fantoni G; Couzens L; Gao J; Plant E; Ye Z; Eichelberger MC; Wan H
    J Virol; 2016 Jan; 90(1):117-28. PubMed ID: 26468531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
    Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
    Momont C; Dang HV; Zatta F; Hauser K; Wang C; di Iulio J; Minola A; Czudnochowski N; De Marco A; Branch K; Donermeyer D; Vyas S; Chen A; Ferri E; Guarino B; Powell AE; Spreafico R; Yim SS; Balce DR; Bartha I; Meury M; Croll TI; Belnap DM; Schmid MA; Schaiff WT; Miller JL; Cameroni E; Telenti A; Virgin HW; Rosen LE; Purcell LA; Lanzavecchia A; Snell G; Corti D; Pizzuto MS
    Nature; 2023 Jun; 618(7965):590-597. PubMed ID: 37258672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017.
    Catani JPP; Smet A; Ysenbaert T; Vuylsteke M; Bottu G; Mathys J; Botzki A; Cortes-Garcia G; Strugnell T; Gomila R; Hamberger J; Catalan J; Ustyugova IV; Farrell T; Stegalkina S; Ray S; LaRue L; Saelens X; Vogel TU
    Elife; 2024 May; 12():. PubMed ID: 38805550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody.
    Khalil AM; Piepenbrink MS; Markham I; Basu M; Martinez-Sobrido L; Kobie JJ
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
    Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
    Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
    mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza B virus neuraminidase: a potential target for next-generation vaccines?
    Do THT; Wheatley AK; Kent SJ; Koutsakos M
    Expert Rev Vaccines; 2024; 23(1):39-48. PubMed ID: 38037386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.
    Yasuhara A; Yamayoshi S; Kiso M; Sakai-Tagawa Y; Koga M; Adachi E; Kikuchi T; Wang IH; Yamada S; Kawaoka Y
    Nat Microbiol; 2019 Jun; 4(6):1024-1034. PubMed ID: 30886361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
    Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
    Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.
    Gilchuk IM; Bangaru S; Gilchuk P; Irving RP; Kose N; Bombardi RG; Thornburg NJ; Creech CB; Edwards KM; Li S; Turner HL; Yu W; Zhu X; Wilson IA; Ward AB; Crowe JE
    Cell Host Microbe; 2019 Dec; 26(6):715-728.e8. PubMed ID: 31757769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
    Rijal P; Wang BB; Tan TK; Schimanski L; Janesch P; Dong T; McCauley JW; Daniels RS; Townsend AR; Huang KA
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31748388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Wilson JR; Guo Z; Reber A; Kamal RP; Music N; Gansebom S; Bai Y; Levine M; Carney P; Tzeng WP; Stevens J; York IA
    Antiviral Res; 2016 Nov; 135():48-55. PubMed ID: 27713074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.
    Wan H; Gao J; Xu K; Chen H; Couzens LK; Rivers KH; Easterbrook JD; Yang K; Zhong L; Rajabi M; Ye J; Sultana I; Wan XF; Liu X; Perez DR; Taubenberger JK; Eichelberger MC
    J Virol; 2013 Aug; 87(16):9290-300. PubMed ID: 23785204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.